Dova Pharmaceuticals Provides Update on Development Strategy for Avatrombopag in Immune Thrombocytopenic Purpura (ITP) and Chemotherapy-Induced Thrombocytopenia (CIT)
January 03, 2018 16:05 ET
|
Dova Pharmaceuticals, Inc.
Supplemental NDA for ITP to be submitted in the second half of 2018 Phase 3 Clinical Trial for CIT to begin in the second quarter of 2018 DURHAM, N.C., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Following...
Dova Pharmaceuticals Announces Four Presentations at the 59th American Society of Hematology Annual Meeting
December 04, 2017 16:30 ET
|
Dova Pharmaceuticals, Inc.
DURHAM, N.C., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that the Company will present four abstracts, three of which will be oral presentations, with...
Dova Pharmaceuticals Announces FDA Acceptance of the Avatrombopag New Drug Application (NDA) with Priority Review
November 27, 2017 16:05 ET
|
Dova Pharmaceuticals, Inc.
DURHAM, N.C., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced the New Drug Application (NDA) for avatrombopag has been accepted for filing and has been...
Dova Pharmaceuticals to Present at Evercore ISI Conference
November 21, 2017 08:30 ET
|
Dova Pharmaceuticals, Inc.
DURHAM, N.C., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that Alex Sapir, President and Chief Executive Officer, will present a company overview at...
Dova Pharmaceuticals to Present at Jefferies 2017 London Healthcare Conference
November 10, 2017 08:30 ET
|
Dova Pharmaceuticals, Inc.
DURHAM, N.C., Nov. 10, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that Alex Sapir, President and Chief Executive Officer, will present a company overview at...
Dova Pharmaceuticals Reports Third Quarter 2017 Operating and Financial Results
November 09, 2017 16:05 ET
|
Dova Pharmaceuticals, Inc.
NDA for avatrombopag submitted to FDA Conference call scheduled for 4:30 p.m. EST today DURHAM, N.C., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today reported its...
Dova Pharmaceuticals to Announce Third Quarter 2017 Financial Results on November 9, 2017
November 02, 2017 16:30 ET
|
Dova Pharmaceuticals, Inc.
DURHAM, N.C., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA), a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare...
Dova Pharmaceuticals to Present Phase 3 Avatrombopag Data at the 2017 Liver Meeting of the American Association for the Study of Liver Diseases (AASLD)
October 10, 2017 16:30 ET
|
Dova Pharmaceuticals, Inc.
Detailed Safety and Efficacy Results from ADAPT-1 and ADAPT-2 Phase 3 Trials to be Reported in Oral Presentation Company to Host Investor and Analyst Conference Call and Webcast at 5:00 p.m. on...
Dova Pharmaceuticals Announces New Drug Application Submission to FDA for Avatrombopag, a Second Generation Thrombopoietin Receptor Agonist
September 22, 2017 07:00 ET
|
Dova Pharmaceuticals, Inc.
DURHAM, N.C., Sept. 22, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA), a specialty pharmaceutical company, today announced the submission of a New Drug Application (NDA) to the...
Dova Pharmaceuticals to Present at 2017 Leerink Partners Rare Disease Roundtable
September 20, 2017 16:15 ET
|
Dova Pharmaceuticals, Inc.
DURHAM, N.C., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that Alex Sapir, President and Chief Executive Officer, will present a company overview at...